Syngene’s FY26: A soft year, but the platform keeps expanding

Syngene International closed FY26 with modest growth and weaker profitability, even as the company continued to invest in new capabilities and global capacity. For Q4 FY26, revenue from operations stood at Rs 1,037 crore, up 2% year on year, and up 13% sequentially. The sequential improvement helped end the year on a better note than the earlier quarters, but margins remained under pressure.

For the full year FY26, revenue from operations was Rs 3,739 crore, a 3% increase over FY25. Operating EBITDA margin declined to 25% from 29% in FY25, and PAT before exceptional items came in at Rs 380 crore, down 20% year on year. Management repeatedly pointed to the impact of Librela destocking, linked to a single large molecule biologics client, as a key factor behind the muted performance.

Q4 showed sequential momentum, but margins stayed lower

Syngene’s Q4 financials reflected a modest year-on-year uptick but stronger quarter-on-quarter momentum. Q4 FY26 reported revenue was Rs 1,059 crore, with revenue from operations of Rs 1,037 crore. EBITDA for the quarter was Rs 326 crore, with an EBITDA margin of 30.8% on reported revenue in the investor presentation table (and management commentary referring to an operating margin of around 29%). PAT before exceptional items was Rs 153 crore, while PAT after exceptional items was Rs 148 crore.

Cost lines showed the nature of the margin compression. Staff costs rose sharply, up 19% year on year in Q4 FY26, reflecting investments in talent and the ramp-up of new facilities. Foreign exchange losses were also higher in FY26 versus FY25, and management highlighted hedge losses driven by differences between average and spot hedge rates.

Note: Figures are from the investor presentation table and are consolidated.

FY26 was shaped by Librela headwinds and a higher operating base

For FY26, Syngene delivered reported revenue of Rs 3,809 crore, with revenue from operations at Rs 3,739 crore. EBITDA was Rs 989 crore, down 11% year on year, and EBITDA margin declined to 26% on reported revenue in the table (management also referred to EBITDA margins in the mid-20s). PAT before exceptional items was Rs 380 crore versus Rs 475 crore in FY25.

Management described the year as being “in line with revised guidance” and emphasised that the underlying business continued to show steady momentum, despite the impact of Librela destocking. On the call, management stated that excluding Librela, underlying growth was in high single digits, but did not quantify further.

Syngene also pointed to balance sheet strength and cash generation. Management disclosed free cash generation of Rs 521 crore in FY26 and a closing net cash balance of Rs 1,800 crore. The investor presentation balance sheet highlights shareholders’ funds of Rs 4,839 crore and net fixed assets of Rs 4,046 crore as of March 31, 2026.

Strategy focus: modalities, biologics build-out, and a wider global footprint

The company’s narrative in the investor deck and on the call was centered on building an integrated platform that spans discovery, development, and manufacturing, with more emphasis on emerging modalities. In Q4 FY26, Syngene commenced operations at its ADC discovery laboratory. This was positioned as complementary to the recently added GMP bioconjugation suite, together forming an end-to-end ADC capability from discovery to manufacturing.

Management also discussed investments in peptides and other novel modalities, aligning with their view that global pharma pipelines are increasingly shifting away from traditional small molecules. On the call, management referenced industry estimates that advanced modalities account for over 40% of clinical pipelines.

On the CDMO side, Syngene spoke about a growing pipeline in the Unit 3 biologics facility in Bengaluru, with increased client interactions from large pharma and emerging biotech during the quarter. The company also discussed progress at the Bayview biologics facility in Baltimore, USA. Management said preparations are progressing and that the company is actively engaging prospective customers as it moves toward operationalization.

The CFO added an important detail: Bayview costs are only partially reflected in the P&L at this stage, and the facility has not yet been fully capitalized. This underscores the ongoing transition phase for the US site.

Syngene also cited commissioning of a new commercial scale facility for liquid-filled hard gelatin capsules, strengthening oral solid dosage capability in its small molecule platform.

FY27 outlook: flat year, stronger second half, and transition in leadership

The key forward-looking message was that FY27 is expected to be broadly flat on revenue, while maintaining EBITDA margins in the mid-20s. Management expects FY27 to start muted, with H2 FY27 being meaningfully stronger than H1 as new contracts ramp up.

Librela continues to dominate the near-term outlook. Management said Q1 and Q2 FY27 will have almost no Librela volumes, with only a minor amount expected toward the end of the year.

FY27 is also set up as a transition year for leadership. Kiran Mazumdar-Shaw shifted from Non-Executive Chairperson to Executive Chairperson effective April 1, 2026. Siddharth Mittal is set to join as Managing Director and CEO effective July 1, 2026, while a new Chief Commercial Officer and Chief Human Resources Officer joined effective May 1, 2026.

Separately, the company’s April 29, 2026 board outcome included a recommended final dividend of Rs 1.25 per share (record date June 26, 2026), and approval to appoint S. R. Batliboi and Associates LLP as statutory auditors for five years, subject to shareholder approval.

Takeaways

Syngene’s FY26 numbers reflect a year dominated by a single large client-related headwind, alongside a higher cost base from capacity additions and people investments. At the same time, the company continued to expand into emerging modalities, strengthened its biologics manufacturing platform, and maintained a net cash position that provides resilience.

FY27 is being positioned as a reset year, with flat revenue guidance, mid-20s margins, and growth weighted to the second half. Management’s message is that the Librela impact should largely wash out by the end of FY27, setting up a stronger growth trajectory from FY28 as new capabilities and a healthier pipeline begin to translate into revenue.